Keros Therapeutics Quarterly Balance Sheets Chart
Quarterly
|
Annual
Keros Therapeutics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||||
| current assets: | ||||||||||||||||||||||
| cash and cash equivalents | 690,215,000 | 720,541,000 | 559,931,000 | 530,684,000 | 405,863,000 | 442,443,000 | 331,147,000 | 287,893,000 | 322,026,000 | 351,429,000 | 279,048,000 | 239,426,000 | 215,621,000 | 228,586,000 | 230,042,000 | 221,349,000 | 237,113,000 | 255,203,000 | 265,876,000 | 133,810,000 | 144,687,000 | 54,518,000 |
| accounts receivable | 15,816,000 | 17,291,000 | 2,742,000 | 388,000 | 4,000 | 226,000 | 143,000 | 18,000,000 | 100,000 | |||||||||||||
| prepaid expenses and other current assets | 26,777,000 | 21,677,000 | 26,220,000 | 20,974,000 | 26,847,000 | 20,457,000 | 16,003,000 | 16,542,000 | 12,282,000 | 10,793,000 | 6,719,000 | 6,449,000 | 6,736,000 | 2,634,000 | 3,398,000 | 4,725,000 | 4,204,000 | 779,000 | 1,850,000 | 2,606,000 | 3,830,000 | 1,197,000 |
| total current assets | 732,808,000 | 759,509,000 | 588,893,000 | 552,046,000 | 432,714,000 | 463,126,000 | 347,293,000 | 304,435,000 | 334,308,000 | 362,222,000 | 285,767,000 | 245,875,000 | 222,357,000 | 231,220,000 | 251,440,000 | 226,074,000 | 241,417,000 | 255,982,000 | 267,726,000 | 136,416,000 | 148,517,000 | 58,539,000 |
| operating lease right-of-use assets | 18,072,000 | 18,667,000 | 19,251,000 | 19,823,000 | 14,649,000 | 14,995,000 | 15,334,000 | 15,669,000 | 16,010,000 | 16,364,000 | 15,548,000 | 447,000 | 658,000 | 864,000 | 1,067,000 | 1,265,000 | 676,000 | 779,000 | 878,000 | 976,000 | 1,025,000 | 1,116,000 |
| property and equipment | 4,836,000 | 4,473,000 | 4,237,000 | 4,366,000 | 4,292,000 | 4,434,000 | 4,134,000 | 3,357,000 | 3,087,000 | 2,933,000 | 2,021,000 | 1,680,000 | 1,652,000 | 1,456,000 | 1,335,000 | 1,295,000 | 1,253,000 | 854,000 | 724,000 | 739,000 | 781,000 | 822,000 |
| restricted cash | 1,449,000 | 1,449,000 | 1,449,000 | 1,449,000 | 1,212,000 | 1,212,000 | 1,212,000 | 1,212,000 | 1,327,000 | 1,327,000 | 1,327,000 | 1,327,000 | 1,327,000 | 1,327,000 | 1,327,000 | 1,328,000 | 115,000 | 115,000 | 115,000 | 115,000 | 115,000 | 115,000 |
| other long-term assets | 463,000 | 1,587,000 | 2,155,000 | 2,052,000 | 1,574,000 | 1,574,000 | 1,590,000 | |||||||||||||||
| total assets | 757,165,000 | 784,561,000 | 615,886,000 | 579,271,000 | 455,022,000 | 485,819,000 | 370,025,000 | 326,247,000 | 356,306,000 | 384,436,000 | 306,781,000 | 252,550,000 | 226,661,000 | 235,142,000 | 255,251,000 | 229,962,000 | 243,461,000 | 257,730,000 | 269,443,000 | 138,246,000 | 150,438,000 | 60,592,000 |
| liabilities and stockholders' equity | ||||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||||
| accounts payable | 5,267,000 | 6,636,000 | 4,602,000 | 4,981,000 | 6,535,000 | 4,986,000 | 5,450,000 | 3,867,000 | 4,146,000 | 4,682,000 | 3,339,000 | 2,655,000 | 7,660,000 | 3,064,000 | 3,645,000 | 2,811,000 | 1,372,000 | 3,008,000 | 2,149,000 | 1,716,000 | 4,852,000 | 2,426,000 |
| current portion of operating lease liabilities | 2,230,000 | 2,102,000 | 1,978,000 | 1,857,000 | 1,096,000 | 1,050,000 | 1,005,000 | 611,000 | 455,000 | 455,000 | 670,000 | 884,000 | 862,000 | 843,000 | 449,000 | 436,000 | 423,000 | 412,000 | 400,000 | 388,000 | ||
| accrued expenses and other current liabilities | 19,964,000 | 17,290,000 | 20,870,000 | 22,169,000 | 13,614,000 | 12,682,000 | 17,918,000 | 12,223,000 | 11,949,000 | 10,776,000 | 12,753,000 | 8,415,000 | 7,123,000 | 7,700,000 | 7,339,000 | 7,361,000 | 5,710,000 | 5,506,000 | 4,612,000 | 4,697,000 | 3,042,000 | 6,022,000 |
| deferred revenue | 925,000 | 3,308,000 | ||||||||||||||||||||
| current tax liability | 6,321,000 | 10,043,000 | ||||||||||||||||||||
| total current liabilities | 34,707,000 | 39,379,000 | 27,450,000 | 29,007,000 | 21,245,000 | 18,718,000 | 24,373,000 | 16,701,000 | 16,095,000 | 15,458,000 | 16,547,000 | 11,525,000 | 15,453,000 | 11,648,000 | 11,846,000 | 11,015,000 | 7,531,000 | 8,950,000 | 7,184,000 | 6,825,000 | 8,294,000 | 8,836,000 |
| operating lease liabilities, net of current portion | 15,724,000 | 16,311,000 | 16,883,000 | 17,429,000 | 12,861,000 | 13,154,000 | 13,439,000 | 13,704,000 | 13,951,000 | 13,994,000 | 12,811,000 | 231,000 | 453,000 | 242,000 | 361,000 | 476,000 | 586,000 | 692,000 | 797,000 | |||
| total liabilities | 50,431,000 | 55,690,000 | 44,333,000 | 46,436,000 | 34,106,000 | 31,872,000 | 37,812,000 | 30,405,000 | 30,046,000 | 29,452,000 | 29,358,000 | 11,525,000 | 15,453,000 | 11,648,000 | 12,077,000 | 11,484,000 | 7,805,000 | 9,358,000 | 7,722,000 | 7,488,000 | 9,077,000 | 9,737,000 |
| stockholders' equity: | ||||||||||||||||||||||
| preferred stock, par value of 0.0001 per share; 10,000,000 shares authorized as of june 30, 2025 and december 31, 2024; no shares issued and outstanding | ||||||||||||||||||||||
| series a junior participating preferred stock, par value of 0.0001 per share; 500,000 and no shares authorized as of june 30, 2025 and december 31, 2024, respectively; no shares issued and outstanding | ||||||||||||||||||||||
| common stock | 4,000 | 4,000 | 4,000 | 4,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 1,000 |
| additional paid-in capital | 1,157,754,000 | 1,149,195,000 | 1,140,328,000 | 1,055,584,000 | 890,710,000 | 878,484,000 | 713,636,000 | 637,022,000 | 628,000,000 | 619,219,000 | 505,855,000 | 439,739,000 | 386,413,000 | 371,433,000 | 366,927,000 | 335,291,000 | 332,172,000 | 329,266,000 | 326,730,000 | 185,091,000 | 183,658,000 | 6,674,000 |
| accumulated deficit | -451,024,000 | -420,328,000 | -568,779,000 | -522,753,000 | -469,797,000 | -424,540,000 | -381,426,000 | -341,183,000 | -301,743,000 | -264,238,000 | -228,434,000 | -198,716,000 | -175,207,000 | -147,941,000 | -123,755,000 | -116,815,000 | -96,518,000 | -80,896,000 | -65,011,000 | -54,335,000 | -42,299,000 | -31,542,000 |
| total stockholders' equity | 706,734,000 | 728,871,000 | 532,835,000 | 420,916,000 | 453,947,000 | 295,842,000 | 326,260,000 | 354,984,000 | 241,025,000 | 211,208,000 | 223,494,000 | 218,478,000 | 235,656,000 | 248,372,000 | 130,758,000 | 141,361,000 | ||||||
| total liabilities and stockholders' equity | 757,165,000 | 784,561,000 | 579,271,000 | 455,022,000 | 485,819,000 | 326,247,000 | 356,306,000 | 384,436,000 | 252,550,000 | 226,661,000 | 235,142,000 | 229,962,000 | 243,461,000 | 257,730,000 | ||||||||
| preferred stock, par value of 0.0001 per share; 10,000,000 shares authorized as of march 31, 2025 and december 31, 2024; no shares issued and outstanding | ||||||||||||||||||||||
| other long term assets | 2,056,000 | 2,052,000 | 2,118,000 | 82,000 | ||||||||||||||||||
| liabilities and stockholders’ equity | ||||||||||||||||||||||
| commitments and contingencies | ||||||||||||||||||||||
| stockholders’ equity: | ||||||||||||||||||||||
| preferred stock, par value of 0.0001 per share; 10,000,000 shares authorized as of december 31, 2024 and december 31, 2023; no shares issued and outstanding | ||||||||||||||||||||||
| total stockholders’ equity | 571,553,000 | 332,213,000 | 277,423,000 | 243,174,000 | 261,721,000 | |||||||||||||||||
| total liabilities and stockholders’ equity | 615,886,000 | 370,025,000 | 306,781,000 | 255,251,000 | ||||||||||||||||||
| preferred stock, par value of 0.0001 per share; 10,000,000 shares authorized as of september 30, 2024 and december 31, 2023, respectively; no shares issued and outstanding | ||||||||||||||||||||||
| preferred stock, par value of 0.0001 per share; 10,000,000 shares authorized as of june 30, 2024 and december 31, 2023, respectively; no shares issued and outstanding | ||||||||||||||||||||||
| preferred stock, par value of 0.0001 per share; 10,000,000 shares authorized as of march 31, 2024 and december 31, 2023, respectively; no shares issued and outstanding | ||||||||||||||||||||||
| preferred stock, par value of 0.0001 per share; 10,000,000 shares authorized as of december 31, 2023 and december 31, 2022, respectively; no shares issued and outstanding | ||||||||||||||||||||||
| preferred stock, par value of 0.0001 per share; 10,000,000 shares authorized as of december 31, 2022 and december 31, 2021, respectively; no shares issued and outstanding | ||||||||||||||||||||||
| other long-term asset | 3,221,000 | 667,000 | 275,000 | |||||||||||||||||||
| other liabilities | 16,000 | 32,000 | 47,000 | 62,000 | 77,000 | 91,000 | 104,000 | |||||||||||||||
| deferred initial public offering costs | ||||||||||||||||||||||
| research and development incentive receivable | 805,000 | |||||||||||||||||||||
| liabilities, convertible preferred stock and stockholders’ equity | ||||||||||||||||||||||
| preferred stock tranche liability | ||||||||||||||||||||||
| series a convertible preferred stock, par value of 0.0001 per share; 0 and 10,000,000 shares authorized as of december 31, 2020 and december 31, 2019, respectively; 0 and 4,607,652 shares issued and outstanding as of december 31, 2020 and december 31, 2019, respectively; liquidation and redemption value of 0 as of december 31, 2020 | ||||||||||||||||||||||
| series a-1 convertible preferred stock, par value of 0.0001 per share; 0 and 800,000 shares authorized as of december 31, 2020 and december 31, 2019, respectively; 0 and 368,612 shares issued and outstanding as of december 31, 2020 and december 31, 2019, respectively; liquidation and redemption value of 0 as of december 31, 2020 | ||||||||||||||||||||||
| series b-1 convertible preferred stock, par value of 0.0001 per share; 0 and 3,427,004 shares authorized as of december 31, 2020 and december 31, 2019, respectively; 0 and 1,579,043 shares issued and outstanding as of december 31, 2020 and december 31, 2019, respectively; liquidation and redemption value of 0 as of december 31, 2020 | ||||||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders’ equity | 269,443,000 | |||||||||||||||||||||
| deferred ipo costs | 2,019,000 | |||||||||||||||||||||
| liabilities, convertible preferred stock and stockholders' equity | ||||||||||||||||||||||
| series a convertible preferred stock, par value of 0.0001 per share; 0 and 10,000,000 shares authorized as of september 30, 2020 and december 31, 2019, respectively; 0 and 4,607,652 shares issued and outstanding as of september 30, 2020 and december 31, 2019, respectively; liquidation and redemption value of 0 as of september 30, 2020 | ||||||||||||||||||||||
| series a-1 convertible preferred stock, par value of 0.0001 per share; 0 and 800,000 shares authorized as of september 30, 2020 and december 31, 2019, respectively; 0 and 368,612 shares issued and outstanding as of september 30, 2020 and december 31, 2019, respectively; liquidation and redemption value of 0 as of september 30, 2020 | ||||||||||||||||||||||
| series b-1 convertible preferred stock, par value of 0.0001 per share; 0 and 3,427,004 shares authorized as of september 30, 2020 and december 31, 2019, respectively; 0 and 1,579,043 shares issued and outstanding as of september 30, 2020 and december 31, 2019, respectively; liquidation and redemption value of 0 as of september 30, 2020 | ||||||||||||||||||||||
| stockholders' equity | ||||||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders' equity | 138,246,000 | 150,438,000 | ||||||||||||||||||||
| series a convertible preferred stock, par value of 0.0001 per share; 0 and 10,000,000 shares authorized as of june 30, 2020 and december 31, 2019, respectively; 0 and 4,607,652 shares issued and outstanding as of june 30, 2020 and december 31, 2019, respectively; liquidation and redemption value of 0 as of june 30, 2020 | ||||||||||||||||||||||
| series a-1 convertible preferred stock, par value of 0.0001 per share; 0 and 800,000 shares authorized as of june 30, 2020 and december 31, 2019, respectively; 0 and 368,612 shares issued and outstanding as of june 30, 2020 and december 31, 2019, respectively; liquidation and redemption value of 0 as of june 30, 2020 | ||||||||||||||||||||||
| series b-1 convertible preferred stock, par value of 0.0001 per share; 0 and 3,427,004 shares authorized as of june 30, 2020 and december 31, 2019, respectively; 0 and 1,579,043 shares issued and outstanding as of june 30, 2020 and december 31, 2019, respectively; liquidation and redemption value of 0 as of june 30, 2020 | ||||||||||||||||||||||
| liabilities, convertible preferred stock and stockholders' deficit | ||||||||||||||||||||||
| series a convertible preferred stock, par value of 0.0001 per share; 10,000,000 shares authorized as of march 31, 2020 and december 31, 2019; 4,607,652 shares issued and outstanding as of march 31, 2020 and december 31, 2019; liquidation and redemption value of 12,471 as of march 31, 2020 | 9,891,000 | |||||||||||||||||||||
| series a-1 convertible preferred stock, par value of 0.0001 per share; 800,000 shares authorized as of march 31, 2020 and december 31, 2019; 368,612 shares issued and outstanding as of march 31, 2020 and december 31, 2019; liquidation and redemption value of 1,191 as of march 31, 2020 | 944,000 | |||||||||||||||||||||
| series b-1 convertible preferred stock, par value of 0.0001 per share; 3,427,004 shares authorized as of march 31, 2020 and december 31, 2019; 1,579,043 shares issued and outstanding as of march 31, 2020 and december 31, 2019; liquidation and redemption value of 12,826 as of march 31, 2020 | 9,106,000 | |||||||||||||||||||||
| series c convertible preferred stock, par value of 0.0001 per share; 9,049,783 and 0 shares authorized as of march 31, 2020 and december 31, 2019, respectively; 4,169,822 and 0 shares issued and outstanding as of march 31, 2020 and december 31, 2019, respectively; liquidation and redemption value of 56,356 as of march 31, 2020 | 55,781,000 | |||||||||||||||||||||
| stockholders' deficit: | ||||||||||||||||||||||
| total stockholders' deficit | -24,867,000 | |||||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders' deficit | 60,592,000 |
We provide you with 20 years of balance sheets for Keros Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Keros Therapeutics. Explore the full financial landscape of Keros Therapeutics stock with our expertly curated balance sheets.
The information provided in this report about Keros Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.